Smart port.
Early detection.
Better outcomes.
THE NEXT GENERATION IN REMOTE PATIENT MONITORING
Advances in personalized medicine and digital health are transforming cancer care — but the implantable chemotherapy port has remained unchanged for decades. NXgenPort changes that.
Our first-of-its-kind smart chemo-port integrates optical sensing and machine learning directly into the device monitoring blood cell dynamics in vivo — so clinicians can detect dangerous treatment complications before they become emergency hospitalizations. Same proven port. Smarter care.
WHAT IS
NXGEN PORT?
Proven sensor technology
Remotely measure physiological changes in vivo
Digital health platform with data analysis
Allows early intervention by care team
This product has not received market authorization.
THE
PROBLEM
COSTS $2.3 BILLION ANNUALLY
50%
Up to 50% of patients on myelosuppressive chemotherapy develop neutropenia, placing them at significantly elevated risk for infection and life-threatening complications.
20%
20% of patients have complications ranging from minor to major, most frequently infections, thrombosis, hospitalization leading to higher medical and treatment costs.
25%
In real-world settings, studies report that 21–27% of women receiving trastuzumab — particularly in combination with anthracyclines — experience clinically significant cardiac dysfunction or decline.
25%
25% of patients have to delay or cancel treatment due to poor blood counts on treatment days.
This product has not received market authorization.
IMPROVING TREATMENT
1
REMOTE PATIENT MONITORING
Physiologic changes and trends gathered in vivo.
2
DATA + ANALYTICS
Information about a patient's health status analyzed on a platform.
3
REPORT TO PROVIDER
Relevant measures and actionable data shared with care team.
4
PHYSICIANS TAKE ACTION
Data drives decisions about patient management.
This product has not received market authorization.
How does NXgenPort work?
This product has not yet received market authorization.
VALUE TO STAKEHOLDERS
PHYSICIANS
-
Will provide early indication of infection
-
Remote patient monitoring
-
Put “eyes and hands” on patients
-
Actionable data
-
Maximize focus on the patients who have the greatest health needs
PATIENTS
-
Will assess baseline of health before treatment begins
-
Awareness of acceptable symptoms
-
Alert to infection
​
-
Peace of mind
-
Limits “micro-traumas”
INSURANCE
PAYERS
-
Potentially reduce unexpected hospitalizations
-
Manage costs due to adverse events
​
-
Insights around patient risk profile
PROVIDERS
-
Potentially reduce treatment cancelations or delays
-
Longitudinal patient data
-
Manage costs
​
-
Increase efficiency
PHARMA
-
Virtual clinical trial support
​
-
Passive data collection
-
Adherence and drug efficacy
BEYOND THE MVP, NXGENPORT WILL
GATHER DATA FOR CARE TEAMS:
-
Changes in heart function
-
Specific blood cell counts
-
Detect oxygen levels
-
Measure body temperature
-
Track Proteins (i.e., hemoglobin)
-
Surveil for cancer recurrance
-
Detect device leakage or failure
TEAM
Cathy Skinner, MA
Co-founder/Co-inventor
Chief Executive Officer
-
Entrepreneur with 12 years of startup experience (Thrivors.com and TheArtofWell.com).
-
Nationally recognized Cancer Exercise Specialist with the American College of Sports Medicine.
-
12 years of working face-to-face with cancer patients and survivors providing wellness programs.
-
Invited panelist and guest speaker, Cancer Survivorship Conferences, Employer Benefits, Pharma Patient Advocacy conferences.
-
Former Chair of the Minnesota Cancer Alliance.
-
Board member with one non-profit organization.
Rosanne Welcher, PhD, MBA, RAC
Co-founder/Co-inventor
Chief Operating Officer
-
Award-winning R&D and Business Leader with cross-functional expertise in Medical Devices/IVD business development, product development, regulatory and clinical affairs, quality assurance, manufacturing and commercialization.
-
Over 25 years in med devices/IVD with people management experience.
-
Former CSO Agilent Technologies, Companion Diagnostics.
-
Invited guest speaker, Personalized Medicine, Regulatory/Clinical and IVD conferences.
-
17 issued patents.
-
Board Director with two non-profit organizations.
Kelly Christian, MS
R&D and Engineering
-
30 years bringing new medical devices to market.
​
-
20 years developing new chemo ports including developing the first PowerPort (TM).
​
-
Former Senior Director at Becton Dickinson as a biomedical engineer, team leader, and program director.
​
-
Launched products with an annual value of almost a billion dollars and improved outcomes for millions of patients worldwide.
​
-
30 issued patents related to ports.
​
-
Industrial Advisory Board Member for the school of Biomedical Engineering for the University of Utah.
ADVISORS
Tufia Haddad, MD
Oncology, Product Advisor and
Patient/Physician Perspectives
Dean Gesme, MD
Board Chair, Oncology
Rich Nazarian, BS, MS
Engineering, Business Strategy and Partnerships
Serge Alexanian, MD
Medical Advisor
Surgical and Hospital Liaison
Formerly of
Nancy Lelicoff, MS
Engineering, Regulatory, Quality and Research
Formerly of
Lisa Suennen
Digital Health Strategy and Investor Relations
Alan Feinerman, PhD
Research and Device Design
Vincent Kuenen, BS, MS
Engineering, Software Development and Patient Advocate
